Difference between revisions of "Acute myeloid leukemia, IDH-mutated"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m
Line 6: Line 6:
 
|-
 
|-
 
| style="background-color:#F0F0F0; width:15%" |[[File:MartinSchoen.jpg|frameless|upright=0.3|center]]
 
| style="background-color:#F0F0F0; width:15%" |[[File:MartinSchoen.jpg|frameless|upright=0.3|center]]
| style="width:35%" |<big>[[User:Marteens|Martin Schoen, MD, MPH]]<br>Chicago, IL</big>
+
| style="width:35%" |<big>[[User:Marteens|Martin Schoen, MD, MPH]]<br>St. Louis, MO</big>
 
|-
 
|-
 
|}
 
|}

Revision as of 15:59, 10 May 2018


Page editor
MartinSchoen.jpg
Martin Schoen, MD, MPH
St. Louis, MO

Note: these are biomarker-specific regimens for patients with IDH1 or IDH2-mutated AML, please see the main AML page for other regimens.

8 regimens on this page
8 variants on this page


Relapsed or refractory, salvage therapy

Enasidenib monotherapy

back to top

Regimen

FDA-recommended dose
Study Evidence Efficacy
Stein et al. 2017 Phase I/II ORR: 40%

This is the dose used in the phase II expansion cohort; enrolled patients were required to have IDH2-mutated advanced myeloid malignancies.

Chemotherapy

28-day cycles

References

  1. Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, Kantarjian HM, Collins R, Patel MR, Frankel AE, Stein A, Sekeres MA, Swords RT, Medeiros BC, Willekens C, Vyas P, Tosolini A, Xu Q, Knight RD, Yen KE, Agresta S, de Botton S, Tallman MS. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 Aug 10;130(6):722-731. Epub 2017 Jun 6. link to original article contains verified protocol link to PMC article PubMed